Sailong Pharmaceutical Group Co., Ltd. (002898.SZ)
002898.SZ Stock Price Chart
Explore Sailong Pharmaceutical Group Co., Ltd. interactive price chart. Choose custom timeframes to analyze 002898.SZ price movements and trends.
002898.SZ Company Profile
Discover essential business fundamentals and corporate details for Sailong Pharmaceutical Group Co., Ltd. (002898.SZ) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
13 Sept 2017
Employees
483.00
Website
https://www.sailong.cnCEO
Nangui Cai
Description
Sailong Pharmaceutical Group Co., Ltd. researches, develops, produces, markets, and services pharmaceutical intermediates, raw materials, and preparations in China. The company offers esomeprazole sodium, ornithine aspartate, thymus, argatroban, gaicycline, monosialotetrahexose ganglioside sodium, cerebroprotein hydrolysate, milrinone, parecoxib sodium, tranexamic acid, clindamycin phosphate, and pantoprazole sodium products. It provides its products for therapeutic areas, such as cardiovascular, cerebrovascular, nerve, digestive system, proton pump inhibitors, anti-infectives, anti-bleeding medicine, analgesics, and other fields. The company was formerly known as Zhuhai Sailong Pharmaceutical Co.,Ltd. and changed its name to Sailong Pharmaceutical Group Co., Ltd. in September 2021. Sailong Pharmaceutical Group Co., Ltd. was founded in 2002 and is based in Zhuhai, China.
002898.SZ Financial Timeline
Browse a chronological timeline of Sailong Pharmaceutical Group Co., Ltd. corporate events including earnings releases, dividend announcements, and stock splits.
Earnings released on 16 May 2025
EPS came in at -¥0.17 , while revenue for the quarter reached ¥44.82M .
Earnings released on 31 Mar 2025
EPS came in at -¥0.01 , while revenue for the quarter reached ¥54.09M .
Earnings released on 29 Sept 2024
EPS came in at -¥0.03 , while revenue for the quarter reached ¥61.47M .
Earnings released on 29 Jun 2024
EPS came in at ¥0.00 , while revenue for the quarter reached ¥85.45M .
Dividend declared on 28 Jun 2024
A dividend of ¥0.02 per share was announced, adjusted to ¥0.02. The dividend was paid on 28 Jun 2024.
Earnings released on 16 May 2024
EPS came in at ¥0.01 , while revenue for the quarter reached ¥69.48M .
Earnings released on 3 Apr 2024
EPS came in at ¥0.03 , while revenue for the quarter reached ¥85.25M .
Earnings released on 30 Sept 2023
EPS came in at ¥0.01 , while revenue for the quarter reached ¥68.59M .
Earnings released on 30 Jun 2023
EPS came in at -¥0.00 , while revenue for the quarter reached ¥77.36M .
Earnings released on 31 Mar 2023
EPS came in at ¥0.02 , while revenue for the quarter reached ¥79.43M .
Earnings released on 1 Jan 2023
EPS came in at -¥0.22 , while revenue for the quarter reached ¥71.36M .
Earnings released on 30 Sept 2022
EPS came in at ¥0.00 , while revenue for the quarter reached ¥61.47M .
Earnings released on 30 Jun 2022
EPS came in at -¥0.00 , while revenue for the quarter reached ¥69.16M .
Earnings released on 31 Mar 2022
EPS came in at ¥0.01 , while revenue for the quarter reached ¥62.21M .
Earnings released on 31 Dec 2021
EPS came in at -¥0.20 , while revenue for the quarter reached ¥61.65M .
Earnings released on 30 Sept 2021
EPS came in at ¥0.01 , while revenue for the quarter reached ¥56.39M .
Earnings released on 30 Jun 2021
EPS came in at ¥0.04 , while revenue for the quarter reached ¥60.74M .
Earnings released on 30 Apr 2021
EPS came in at -¥0.26 , while revenue for the quarter reached -¥6.16M .
Earnings released on 31 Mar 2021
EPS came in at ¥0.01 , while revenue for the quarter reached ¥68.29M .
Earnings released on 30 Sept 2020
EPS came in at -¥0.05 , while revenue for the quarter reached ¥38.41M .
002898.SZ Stock Performance
Access detailed 002898.SZ performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.